Maspin subcellular expression in wild-type and mutant TP53 gastric cancers

被引:13
|
作者
Gurzu, Simona [1 ,2 ]
Jung, Ioan [1 ]
Sugimura, Haruhiko [3 ]
Stefan-van Staden, Raluca Ioana [4 ]
Yamada, Hidetaka [3 ]
Natsume, Hiroko [3 ]
Iwashita, Yuji [3 ]
Szodorai, Rita [1 ]
Szederjesi, Janos [5 ]
机构
[1] George Emil Palade Univ Med Pharm Sci & Technol, Dept Pathol, Targu Mures 540139, Mures, Romania
[2] George Emil Palade Univ Med Pharm Sci & Technol, Res Ctr, Targu Mures 540139, Mures, Romania
[3] Hamamatsu Univ Sch Med, Dept Tumor Pathol, Hamamatsu, Shizuoka 4313192, Japan
[4] Natl Inst Res Electrochem & Condensed Matter, Bucharest 060021, Romania
[5] George Emil Palade Univ Med Pharm Sci & Technol, Intens Care Unit, Targu Mures 540139, Mures, Romania
关键词
p53; TP53; gene; Maspin; Gastric cancer; Carcinoma; COLORECTAL-CANCER; P53; SYSTEM;
D O I
10.4251/wjgo.v12.i7.741
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND Although the role of p53 in the evolution and prognosis of gastric cancer (GC) has been extensively examined, the exact mechanism of action is incompletely understood. In the last years, p53-target genes were supposed to be involved in the p53 pathway. One of them is the tumor-suppressor gene Maspin, which codifies the protein with the same name. Maspin activity depends on its subcellular localization. To our knowledge, the possible role ofTP53gene in Maspin subcellular localization, in GC cells, has not yet been studied in a large number of human samples. AIM To evaluate the possible role of wild-type and mutated p53 in Maspin subcellular localization. METHODS The present study included 266 consecutive patients with GC in whichTP53gene status, and mutations in exons 2 to 11, respectively, were analyzed and correlated with immunohistochemical expression of p53 and Maspin. RESULTS None of the 266 cases showed mutations in exon 9. The rate ofTP53mutations was 33.83%. The mutation rate was slightly higher in distally-located GCs, with a lower degree (<= 5 buds/ high power fields) of dyscohesivity (P< 0.01). The wild-type cases had a longer survival, compared with mutant GCs, especially in patients without lymph node metastases, despite the high depth of tumor infiltration (P= 0.01). The Dukes-MAC-like staging system was proved to have the most significant independent prognostic value (P< 0.01). The statistical correlations proved thatTP53gene mutations in exon 7 might induce knockdown of Maspin, but wild-type p53 can partially restore nuclear Maspin expression and decrease the metastatic potential of gastric adenocarcinoma cells. CONCLUSION Downregulated Maspin might be induced by mutations in exon 7 of theTP53gene but wild-type p53 can partially restore nuclear Maspin expression. These findings should be proved in experimental studies.
引用
收藏
页码:741 / 755
页数:15
相关论文
共 50 条
  • [1] Maspin subcellular expression in wild-type and mutant TP53 gastric cancers
    Simona Gurzu
    Ioan Jung
    Haruhiko Sugimura
    Raluca Ioana Stefan-van Staden
    Hidetaka Yamada
    Hiroko Natsume
    Yuji Iwashita
    Rita Szodorai
    Janos Szederjesi
    World Journal of Gastrointestinal Oncology, 2020, (07) : 741 - 755
  • [2] Expression of wild-type and mutated TP53 in breast carcinomas
    Baumbusch, LO
    Myhre, S
    Langerod, A
    Bergamaschi, A
    Johnsen, H
    Geisler, S
    Lonning, PE
    Borresen-Dale, AL
    BREAST CANCER RESEARCH, 2005, 7 (Suppl 2) : S53 - S53
  • [3] Differential angiogenic gene expression in TP53 wild-type and mutant ovarian cancer cell lines
    Davidson, Brittany Anne
    Rubatt, Jennifer M.
    Corcoran, David L.
    Teoh, Deanna K.
    Bernardini, Marcus Q.
    Grace, Lisa A.
    Soper, William John
    Berchuck, Andrew
    Siamakpour-Reihani, Sharareh
    Chen, Wei
    Owzar, Kouros
    Murphy, Susan K.
    Secord, Angeles Alvarez
    FRONTIERS IN ONCOLOGY, 2014, 4
  • [4] Wild-type sequence of TP53, intron 7
    Eicheler, W
    Baumann, M
    RADIATION RESEARCH, 2001, 155 (04) : 641 - 641
  • [5] KEVETRIN TARGETS TP53 WILD-TYPE AND MUTANT ACUTE MYELOID LEUKEMIA CELLS
    Napolitano, R.
    De Matteis, S.
    Carloni, S.
    Ghetti, M.
    Liverani, C.
    Bochicchio, M. T.
    di Rora, A. Ghelli Luserna
    Fontana, M. C.
    Padella, A.
    Mercatali, L.
    Menon, K.
    Musuraca, G.
    Martinelli, G.
    Simonetti, G.
    HAEMATOLOGICA, 2020, 105 : S88 - S89
  • [6] Chemokine Network and Overall Survival in TP53 Wild-Type and Mutant Ovarian Cancer
    Ignacio, Rosa Mistica C.
    Lee, Eun-Sook
    Wilson, Andrew J.
    Beeghly-Fadiel, Alicia
    Whalen, Margaret M.
    Son, Deok-Soo
    IMMUNE NETWORK, 2018, 18 (04)
  • [7] How wild-type TP53 is inactivated in undifferentiated-type gastric carcinomas:: Analyses of intratumoral heterogeneity in deletion and mutation of TP53
    Yoshimura, Akinobu
    Sugihara, Hiroyuki
    Ling, Zhi-Qiang
    Peng, Dun-Fa
    Mukaisho, Ken-ichi
    Fujiyama, Yoshihide
    Hattori, Takanori
    PATHOBIOLOGY, 2006, 73 (01) : 40 - 49
  • [8] Kevetrin induces apoptosis in TP53 wild-type and mutant acute myeloid leukemia cells
    Napolitano, Roberta
    De Matteis, Serena
    Carloni, Silvia
    Bruno, Samantha
    Abbati, Giulia
    Capelli, Laura
    Ghetti, Martina
    Bochicchio, Maria Teresa
    Liverani, Chiara
    Mercatali, Laura
    Calistri, Daniele
    Cuneo, Antonio
    Menon, Krishna
    Musuraca, Gerardo
    Martinelli, Giovanni
    Simonetti, Giorgia
    ONCOLOGY REPORTS, 2020, 44 (04) : 1561 - 1573
  • [9] Unraveling the Role of TP53 in Colorectal Cancer Therapy: From Wild-Type Regulation to Mutant
    Li, Wenshu
    Li, Longyuan
    Yang, Huan
    Shi, Chenxi
    Lei, Zhe
    Guo, Lingchuan
    Wang, Yuhong
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2024, 29 (07):
  • [10] Poor survival with wild-type TP53 ovarian cancer?
    Wong, Kwong-Kwok
    Izaguirre, Daisy I.
    Kwan, Suet-Yan
    King, Erin R.
    Deavers, Michael T.
    Sood, Anil K.
    Mok, Samuel C.
    Gershenson, David M.
    GYNECOLOGIC ONCOLOGY, 2013, 130 (03) : 565 - 569